Last Update08 Aug 25Fair value Increased 4.55%
The consensus price target for Aspen Aerogels has increased, reflecting a higher valuation multiple (future P/E rising from 14.46x to 20.08x) despite a notable decline in net profit margin (from 14.47% to 11.75%), resulting in a new fair value estimate of $9.75.
What's in the News
- Ricardo Rodriguez will step down as CFO at the end of Q3 and be succeeded by Grant Thoele, who currently serves as Chief of Staff and VP of Corporate Strategy and Finance.
- The company issued earnings guidance for H2 and full-year 2025, projecting H2 revenue of $140–160 million, net income (loss) of ($7)–$3 million, and FY 2025 revenue of $297–317 million with a net loss of $317–307 million.
- Aspen Aerogels reported a $955,000 impairment of property, plant, and equipment for Q2.
- Aspen Aerogels was dropped from multiple Russell growth and small-cap indices, including the Russell 2000 Growth, Russell 2500 Growth, Russell 3000 Growth, Russell Microcap Growth, and related benchmarks.
Valuation Changes
Summary of Valuation Changes for Aspen Aerogels
- The Consensus Analyst Price Target has risen from $9.17 to $9.75.
- The Future P/E for Aspen Aerogels has significantly risen from 14.46x to 20.08x.
- The Net Profit Margin for Aspen Aerogels has significantly fallen from 14.47% to 11.75%.
Key Takeaways
- Cost reductions and process improvements are enhancing profitability and positioning the company for stronger earnings even at modest revenue levels.
- Strategic focus on EV thermal barriers and U.S.-based manufacturing aligns with regulatory trends, supporting future growth and market share expansion.
- Heavy reliance on key segments and customers, regulatory uncertainty, and ongoing margin pressures threaten growth projections and create revenue and earnings vulnerability.
Catalysts
About Aspen Aerogels- An aerogel technology company, designs, develops, manufactures, and sells aerogel materials primarily for use in the energy industrial, sustainable insulation materials, and electric vehicle (EV) markets in the United States, Canada, Asia, Europe, and Latin America.
- Aspen's cost optimization-reducing fixed costs by ~$65M and streamlining operations-substantially lowers the revenue threshold needed to achieve profitability. This greater operating leverage, combined with a stable cost structure and controlled CapEx, is set to significantly improve EBITDA and net margin even at modest revenue recovery.
- Medium-term visibility into a rebound in project-based Energy Industrial revenues (subsea/LNG), as key customers' 2025 wins and robust project backlogs are expected to drive attractive incremental revenue and high gross margins from 2026 onwards.
- Strong positioning in the EV thermal barrier market with major OEMs like GM, Stellantis, and Daimler, alongside active new quoting and prototyping activities, underpins a path toward multi-year revenue acceleration as electrification in transportation and strict emissions regulations continue to ramp up globally.
- Ongoing process improvements and increased production efficiency at the Rhode Island and Mexico facilities are driving productivity gains and gross margin expansion, further boosting long-term earnings power and resilience to lower EV production volatility.
- Domestic manufacturing capacity and flexible sourcing strategies cater to automaker preferences for U.S.-based supply and position Aspen as a preferred supplier amid intensifying regulations favoring energy efficiency and sustainability, supporting long-term revenue growth and market share gains.
Aspen Aerogels Future Earnings and Revenue Growth
Assumptions
How have these above catalysts been quantified?- Analysts are assuming Aspen Aerogels's revenue will grow by 8.8% annually over the next 3 years.
- Analysts assume that profit margins will increase from -78.5% today to 12.6% in 3 years time.
- Analysts expect earnings to reach $64.8 million (and earnings per share of $0.74) by about August 2028, up from $-311.9 million today. However, there is some disagreement amongst the analysts with the more bearish ones expecting earnings as low as $32.2 million.
- In order for the above numbers to justify the analysts price target, the company would need to trade at a PE ratio of 18.5x on those 2028 earnings, up from -2.0x today. This future PE is lower than the current PE for the US Chemicals industry at 25.5x.
- Analysts expect the number of shares outstanding to grow by 6.85% per year for the next 3 years.
- To value all of this in today's terms, we will use a discount rate of 7.8%, as per the Simply Wall St company report.
Aspen Aerogels Future Earnings Per Share Growth
Risks
What could happen that would invalidate this narrative?- Slower-than-expected demand recovery in the Energy Industrial segment, with continued destocking by distributors and delayed project activity (especially in subsea and LNG markets), exposes Aspen to prolonged revenue weakness and challenges the assumption of strong growth in this core business.
- High customer concentration in the EV Thermal Barrier segment, particularly reliance on GM, poses a risk to future revenues and earnings if GM's EV production or market share stalls or declines, as suggested by management noting production levels tracking IHS forecasts and emphasizing GM's outsized impact.
- Ongoing policy and regulatory volatility in key markets (notably the U.S. EV market) create uncertainty for EV adoption rates and timing of OEM launches, potentially undermining anticipated topline growth and slowing earnings improvement.
- Adjacent OEM programs, design-in activity, and new platform launches outside of current key customers (e.g., Daimler, Stellantis, ACC) have uncertain timelines or significant slippage due to shifting automaker plans and reaction to changing government incentives, posing risk to the realization of outsized growth projections for 2026-2027.
- The need for persistent R&D and capital expenditures to remain competitive combined with achieved cost reductions cycling out of the base may limit further margin expansion, while risks such as commodity price volatility and potential industry-wide pricing pressure could negatively impact future gross margins and net income.
Valuation
How have all the factors above been brought together to estimate a fair value?- The analysts have a consensus price target of $9.583 for Aspen Aerogels based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $14.0, and the most bearish reporting a price target of just $6.0.
- In order for you to agree with the analyst's consensus, you'd need to believe that by 2028, revenues will be $512.1 million, earnings will come to $64.8 million, and it would be trading on a PE ratio of 18.5x, assuming you use a discount rate of 7.8%.
- Given the current share price of $7.47, the analyst price target of $9.58 is 22.1% higher.
- We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.
How well do narratives help inform your perspective?
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.